OxOnc Services

OxOnc Services appears to have been a private, oncology-focused virtual drug development company based in Princeton, New Jersey, operating under related names including OxOnc Development and OxOnc Development LP. The company was formed by experienced pharmaceutical and clinical development executives and focused on designing and executing oncology studies through research networks in Asia and Europe. Its most visible program was a Phase 2 study of crizotinib in East Asian patients with ROS1-positive, ALK-negative advanced non-small cell lung cancer, conducted in collaboration with Pfizer. Publicly available evidence suggests OxOnc was more of a development and partnering vehicle than a broad product-platform company, and current signs indicate it is no longer active.